Article Details
Retrieved on: 2025-01-03 15:48:52
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
Cellectis uses its proprietary gene-editing platform, TALEN, to develop off-the-shelf CAR-T cell therapies for cancer treatment. This approach aims to ...
Article found on: www.theglobeandmail.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here